Mia Weiss, M.D.
Washington University School of Medicine
5
5
1
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+7 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Kieuhoa Vo, M.D.
UCSF - Mission Bay, Benioff Children's Hospital
Shared therapeutic areas:
Worked with same sponsors:
Patrick Thompson, M.D.
UNC Chapel Hill - North Carolina Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Michael Deel, M.D.
Children's Hospital Medical Center, Cincinnati
Shared therapeutic areas:
Worked with same sponsors:
Meghann McManus, D.O.
Sarah Cannon Research Institute, Pediatric Hematology & Oncology
Shared therapeutic areas:
Worked with same sponsors:
William Thomas Cash, M.D.
Children's Healthcare of Atlanta - Arthur M. Blank Hospital
Shared therapeutic areas:
Worked with same sponsors:
Alok Kothari, M.D.
Phoenix Children's Hospital
Shared therapeutic areas:
Worked with same sponsors:
Lars Wagner, M.D.
Children's Hospital Medical Center, Cincinnati
Shared therapeutic areas:
Worked with same sponsors:
Aerang Kim, M.D.
Children's National Hospital - Washington, DC
Shared therapeutic areas:
Worked with same sponsors:
Erin Trovillion, M.D.
Atrium Health Levine Children's Hospital - Carolinas Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Kyle Jackson, M.D.
Indiana University School of Medicine, Riley Hospital for Children
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
All 5 trials loaded